The latest annual World Preview 2019, Outlook to 2024 comes at one of the most exciting points in the industry’s development. There is significant optimism around the launch of new technologies and the approval of the first cell and gene therapies, resulting in prescription drug sales being forecast to reach $1.18trn in 2024.
Evaluate’s report examines the other key areas that are expected to drive growth, such as orphan drugs which are expected to contribute $239bn of sales in 2024, or oncology therapies with a similar $236bn forecast.
However, as more new technologies reach the market, drug pricing pressure may continue to intensify and damper the overall sales outlook, especially as patent expiries mean almost $200bn of sales are at risk by 2024.
Download your complimentary copy of the World Preview 2019, Outlook to 2024 below.
Thanks for requesting World Preview 2019. You can download your copy here.
Thanks for your interest in Evaluate
The report highlights trends in prescription drug sales, patent risk, R&D spend, global brand sales and market performance by therapy area across the world’s leading pharmaceutical and biotech companies.
The annual report has traditionally sourced all its data from EvaluatePharma. However, for the first time the 2019 report also includes analysis on the risks and rewards of pharma innovation, which features data from new EvaluatePharma Vision.
EvaluatePharma Vision combines our unparalleled consensus forecasts with breakthrough insights on the risk and reward of the R&D landscape. Our clients include all the top 20 global pharma companies, growing biotechs, investment banks, management consultancies, and leading pharmaceutical service providers.
Yes – you can find our full range of data-led reports, covering pharma, biotech, medtech and orphan drugs, on our thought leadership page.